宝济药业通过港交所聆讯 中信证券、国泰海通为联席保荐人

Core Insights - Baoyi Pharmaceutical has passed the main board listing hearing on the Hong Kong Stock Exchange, with CITIC Securities and Guotai Junan acting as joint sponsors [1] - The company's core product, SJ02 (Shengnuowa®), is a long-acting recombinant human follicle-stimulating hormone carboxy-terminal peptide fusion protein for assisted reproduction, which received NDA approval from the National Medical Products Administration in August 2025 [1] - Two other core products, KJ103 (an innovative recombinant immunoglobulin G (IgG) degrading enzyme in Phase III development) and KJ017 (a recombinant hyaluronidase in NDA stage), are in late-stage trials or NDA registration in China [1] - The company's strategy focuses on four key areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [1] - According to Frost & Sullivan, the total clinical addressable market size for the company's four strategic therapeutic areas in China is expected to reach approximately RMB 50 billion by 2033 [1]